Literature DB >> 32068571

Sevoflurane sedation attenuates early cerebral oedema formation through stabilisation of the adherens junction protein beta catenin in a model of subarachnoid haemorrhage: A randomised animal study.

Beatrice Beck-Schimmer1, Tanja Restin, Carl Muroi, Birgit Roth Z'Graggen, Emanuela Keller, Martin Schläpfer.   

Abstract

BACKGROUND: Severe neurological impairment is a problem after subarachnoid haemorrhage (SAH). Although volatile anaesthetics, such as sevoflurane, have demonstrated protective properties in many organs, their use in cerebral injury is controversial. Cerebral vasodilation may lead to increased intracranial pressure (ICP), but at the same time volatile anaesthetics are known to stabilise the SAH-injured endothelial barrier.
OBJECTIVE: To test the effect of sevoflurane on ICP and blood-brain barrier function.
DESIGN: Randomised study. PARTICIPANTS: One hundred male Wistar rats included, 96 analysed.
INTERVENTIONS: SAH was induced by the endoluminal filament method under ketamine/xylazine anaesthesia. Fifteen minutes after sham surgery or induction of SAH, adult male Wistar rats were randomised to 4 h sedation with either propofol or sevoflurane. MAIN OUTCOME MEASURES: Mean arterial pressure (MAP), ICP, extravasation of water (small), Evan's blue (intermediate) and IgG (large molecule) were measured. Zonula occludens-1 (ZO-1) and beta-catenin (β-catenin), as important representatives of tight and adherens junction proteins, were determined by western blot.
RESULTS: Propofol and sevoflurane sedation did not affect MAP or ICP in SAH animals. Extravasation of small molecules was higher in SAH-propofol compared with SAH-sevoflurane animals (79.1 ± 0.9 vs. 78.0 ± 0.7%, P = 0.04). For intermediate and large molecules, no difference was detected (P = 0.6 and P = 0.2). Both membrane and cytosolic fractions of ZO-1 as well as membrane β-catenin remained unaffected by the injury and type of sedation. Decreased cytosolic fraction of β-catenin in propofol-SAH animals (59 ± 15%) was found to reach values of sham animals (100%) in the presence of sevoflurane in SAH animals (89 ± 21%; P = 0.04).
CONCLUSION: This experiment demonstrates that low-dose short-term sevoflurane sedation after SAH in vivo did not affect ICP and MAP and at the same time may attenuate early brain oedema formation, potentially by preserving adherens junctions. TRIAL REGISTRATION: No 115/2014 Veterinäramt Zürich.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32068571     DOI: 10.1097/EJA.0000000000001161

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  5 in total

1.  Inhalational Versus Intravenous Anesthetic Conditioning for Subarachnoid Hemorrhage-Induced Delayed Cerebral Ischemia.

Authors:  Umeshkumar Athiraman; Abhijit V Lele; Menelaos Karanikolas; Vasu Babu Dhulipala; Keshav Jayaraman; Christine Fong; Rainer Kentner; Ravitha Sheolal; Ananth Vellimana; Jeffrey M Gidday; Rajat Dhar; Gregory J Zipfel
Journal:  Stroke       Date:  2021-11-04       Impact factor: 7.914

2.  Sevoflurane Dampens Acute Pulmonary Inflammation via the Adenosine Receptor A2B and Heme Oxygenase-1.

Authors:  Kristian-Christos Ngamsri; Anika Fuhr; Katharina Schindler; Mariana Simelitidis; Michelle Hagen; Yi Zhang; Jutta Gamper-Tsigaras; Franziska M Konrad
Journal:  Cells       Date:  2022-03-24       Impact factor: 6.600

3.  Meta-Analysis of Anesthetic Efficacy and Safety of Propofol in Craniotomy Patients.

Authors:  Qiang Zhou; Ya'nan Han; Jun Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-08-18       Impact factor: 3.009

Review 4.  Role of Anesthetics and Their Adjuvants in Neurovascular Protection in Secondary Brain Injury after Aneurysmal Subarachnoid Hemorrhage.

Authors:  Umeshkumar Athiraman; Gregory J Zipfel
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

5.  Sevoflurane and Desflurane Exposures Following Aneurysmal Subarachnoid Hemorrhage Confer Multifaceted Protection against Delayed Cerebral Ischemia.

Authors:  Keshav Jayaraman; Meizi Liu; Gregory J Zipfel; Umeshkumar Athiraman
Journal:  Biomedicines       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.